3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Melanoma
7
Neoplasms
4
Advanced Cancer
4
Lymphoma, Non-Hodgkin
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Lymphoma, Large B-Cell, Diffuse
2
Liver Neoplasms
2
Hodgkin Disease
2
Various Advanced Cancer
1
Uveal Melanoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Site
1
Microsatellite Unstable Colorectal Cancer
1
Melanoma, Cutaneous Malignant
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Burkitt Lymphoma
1
Advanced Solid Tumors
1
Interventions
tislelizumab
2
sugemalimab
2
pegaspargase
2
IMC-001
2
Gemcitabine
2
tipifarnib
1
relatlimab
1
ontuxizumab
1
gemcitabine-oxaliplatin regimen
1
camrelizumab
1
WW Domain-Containing Oxidoreductase
1
Vitamin B 12
1
Sensitivity and Specificity
1
Oxaliplatin
1
Nivolumab
1
Mannose-Binding Lectin
1
Ice
1
Folic Acid
1
Commerce
1
10-propargyl-10-deazaaminopterin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Extranodal NK-T-Cell
×
relatlimab
×
Clear all
NCT05255601
2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2
Completed
5 enrolled